HCW Biologics (HCWB) Cost of Revenue (2022 - 2026)

HCW Biologics (HCWB) has reported Cost of Revenue for 5 consecutive years, with $229455.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 4278.91% year-over-year to $229455.0; the trailing twelve-month figure through Jun 2026 stood at $268789.0 (down 59.66% YoY), and the FY2025 full-year result was $43386.0, down 97.3% from the prior year.
• Cost of Revenue rose to $229455.0 in Q2 2026 per HCWB's latest filing, from $21609.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $1.4 million in Q3 2022 and bottomed at $4052.0 in Q1 2025.
• Historically, Cost of Revenue has averaged $488080.9 across 5 years, with a median of $341138.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue sank 99.21% in 2025, then surged 4278.91% in 2026.
• Over 5 years, Cost of Revenue stood at $1.1 million in 2022, then retreated by 0.17% to $1.1 million in 2023, then plunged by 70.52% to $315843.0 in 2024, then tumbled by 93.16% to $21609.0 in 2025, then jumped by 961.85% to $229455.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $229455.0, $21609.0, and $12485.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.